Topics:

Second Cancers Associated With Hodgkin’s Disease Treatment

Second Cancers Associated With Hodgkin’s Disease Treatment

ORLANDO—Treatments credited with improving 5-year survival rates for
patients with childhood Hodgkin’s disease may lead to an increased risk of
leukemia, breast cancer, and other neoplasms years later, according to a study
by the Late Effects Study Group (LESG) presented at the American Society of
Hematology annual meeting (abstract 3198).

Smita Bhatia, MD, MPH, director of Epidemiology and Outcomes Research,
Pediatric Hematology and Oncology, City of Hope National Medical Center, Los
Angeles, presented updated findings from a retrospective statistical analysis
to determine the incidence of second cancers and the associated risk factors.

Prior studies had shown late effects of Hodgkin’s disease therapy,
including second cancers, endocrine and pulmonary dysfunction, and cardiac
compromise. "The most devastating of all is second cancers," Dr.
Bhatia said. "There was a 7-fold to 10-fold increase, with females being
at excess risk."

1,380 Hodgkin’s Disease Survivors

Dr. Bhatia’s team analyzed data from the clinical records of 1,380 Hodgkin’s
disease survivors. Patients had been diagnosed in childhood, between 1955 and
1986. The median age at diagnosis was 11 years (range, 1 to 16). The LESG
includes patients from 15 North American and European centers.

Median follow-up for this analysis was 15 years, with some patients followed
for up to 45 years. Males comprised 65% of the group. Eight percent had
received only chemotherapy, 23% had received only radiation therapy, and 69%
both.

A total of 146 patients developed a second cancer, 112 solid tumors, 28
leukemias, and 6 non-Hodgkin’s lymphomas. A multivariate analysis showed that
the relative risk of second cancers was greater for those diagnosed between
ages 10 and 16, those who received both chemotherapy and radiation therapy, and
those who had a recurrence.

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.